Comparative ex vivo activity of novel endoperoxides in multidrug-resistant Plasmodium falciparum and P. vivax

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 10, 2012, Pages 5258-5263

  Marfurt, Jutta ^a   Chalfein, Ferryanto ^b   Prayoga, Pak ^b   Wabiser, Frans ^b   Wirjanata, Grennady ^a   Sebayang, Boni ^c   Piera, Kim A ^a   Wittlin, Sergio ^d,e   Haynes, Richard K ^f   M̈ohrle, Jörg J ^g   Anstey, Nicholas M ^a   Kenangalem, Enny ^b,h   Price, Ric N ^a,i  

^a MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^b Papuan Health and Community Development Foundation (PHCDF)   (Indonesia)

^c EIJKMAN INSTITUTE FOR MOLECULAR BIOLOGY   (Indonesia)

^d SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^e UNIVERSITY OF BASEL   (Switzerland)

^f HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

^g Medicines for Malaria Venture MMV   (Switzerland)

^h District Ministry of Health   (Indonesia)

ⁱ UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; ARTEROLANE; ARTESUNATE; CHLOROQUINE; DIHYDROARTEMISININ; OZ 439; PIPERAQUINE; UNCLASSIFIED DRUG;

ANTIMALARIAL ACTIVITY; ANTIMALARIAL DRUG SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; EX VIVO STUDY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; NONHUMAN; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PRIORITY JOURNAL;

ADAMANTANE; AMODIAQUINE; ANTIMALARIALS; ARTEMISININS; CHLOROQUINE; DRUG RESISTANCE, MULTIPLE; HETEROCYCLIC COMPOUNDS, 1-RING; MICROBIAL SENSITIVITY TESTS; PEROXIDES; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; QUINOLINES; SPIRO COMPOUNDS;

EID: 84866314696     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00283-12     Document Type: Article

References (46)

1. Alin MH, et al. 1995. Efficacy of oral and intravenous artesunate in male Tanzanian adults with Plasmodium falciparum malaria and in vitro susceptibility to artemisinin, chloroquine, and mefloquine. Am. J. Trop. Med. Hyg. 53:639-645. (Pubitemid 26036352)
2. Bacon DJ, et al. 2007. World Antimalarial Resistance Network (WARN) II: in vitro antimalarial drug susceptibility. Malar. J. 6:120.
3. Barbacka K, Baer-Dubowska W. 2011. Searching for artemisinin production improvement in plants and microorganisms. Curr. Pharm. Biotechnol. 12:1743-1751.
4. Brockman A, et al. 2000. Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine. Trans. R. Soc. Trop. Med. Hyg. 94:537-544.
5. Charman SA, et al. 2011. Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. Proc. Natl. Acad. Sci. U. S. A. 108:4400-4405.
6. Dondorp AM, et al. 2009. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 361:455-467.
7. Douglas NM, Anstey NM, Angus BJ, Nosten F, Price RN. 2010. Artemisinin combination therapy for vivax malaria. Lancet Infect. Dis. 10:405-416.
8. Feachem RG, et al. 2010. Shrinking the malaria map: progress and prospects. Lancet 376:1566-1578.
9. Hay SI, Guerra CA, Tatem AJ, Noor AM, Snow RW. 2004. The global distribution and population at risk of malaria: past, present, and future. Lancet Infect. Dis. 4:327-336. (Pubitemid 38692697)
10. Haynes RK, et al. 2006. Artemisone - a highly active antimalarial drug of the artemisinin class. Angew. Chem. Int. ed Engl. 45:2082-2088. (Pubitemid 44105182)
11. Hofer S, et al. 2008. In vitro assessment of the pharmacodynamic properties of DB75, piperaquine, OZ277 and OZ401 in cultures of Plasmodium falciparum. J. Antimicrob. Chemother. 62:1061-1064.
12. Karyana M, et al. 2008. Malaria morbidity in Papua Indonesia, an area with multidrug resistant Plasmodium vivax and Plasmodium falciparum. Malar. J. 7:148.
13. Kindermans JM, Pilloy J, Olliaro P, Gomes M. 2007. Ensuring sustained ACT production and reliable artemisinin supply. Malar. J. 6:125.
14. Kocken CH, et al. 2006. Plasmodium vivax: in vitro susceptibility of blood stages to synthetic trioxolane compounds and the diamidine DB75. Exp. Parasitol. 113:197-200. (Pubitemid 44177462)
15. Kosaisavee V, et al. 2006. Plasmodium vivax: isotopic, PicoGreen, and microscopic assays for measuring chloroquine sensitivity in fresh and cryopreserved isolates. Exp. Parasitol. 114:34-39. (Pubitemid 44188652)
16. Kreidenweiss A, Kremsner PG, Dietz K, Mordmuller B. 2006. In vitro activity of ferroquine (SAR97193) is independent of chloroquine resistance in Plasmodium falciparum. Am. J. Trop. Med. Hyg. 75:1178-1181. (Pubitemid 351627504)
17. Kreidenweiss A, Mordmuller B, Krishna S, Kremsner PG. 2006. Antimalarial activity of a synthetic endoperoxide (RBx-11160/OZ277) against Plasmodium falciparum isolates from Gabon. Antimicrob. Agents Chemother. 50:1535-1537.
18. Lim P, et al. 2009. Pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia. Malar. J. 8:11.
19. Maerki S, et al. 2006. In vitro assessment of the pharmacodynamic properties and the partitioning of OZ277/RBx-11160 in cultures of Plasmodium falciparum. J. Antimicrob. Chemother. 58:52-58. (Pubitemid 44294987)
20. Marfurt J, et al. 2011. Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax. Antimicrob. Agents Chemother. 55:961-966.
21. Mendis K, Sina BJ, Marchesini P, Carter R. 2001. The neglected burden of Plasmodium vivax malaria. Am. J. Trop. Med. Hyg. 64:97-106. (Pubitemid 32552576)
22. Nagelschmitz J, et al. 2008. First assessment in humans of the safety, tolerability, pharmacokinetics, and ex vivo pharmacodynamic antimalarial activity of the new artemisinin derivative artemisone. Antimicrob. Agents Chemother. 52:3085-3091.
23. Noedl H. 2005. Artemisinin resistance: how can we find it? Trends Parasitol. 21:404-405. (Pubitemid 41116714)
24. Noedl H, et al. 2008. Evidence of artemisinin-resistant malaria in western Cambodia. N. Engl. J. Med. 359:2619-2620.
25. Noedl H, Socheat D, Satimai W. 2009. Artemisinin-resistant malaria in Asia. N. Engl. J. Med. 361:540-541.
26. Noedl H, et al. 2001. In vivo-in vitro model for the assessment of clinically relevant antimalarial cross-resistance. Am. J. Trop. Med. Hyg. 65:696- 699.
27. Obaldia N, et al. 2009. Evaluation of artemisone combinations in Aotus monkeys infected with Plasmodium falciparum. Antimicrob. Agents Chemother. 53:3592-3594.
28. Olliaro P, Wells TN. 2009. The global portfolio of new antimalarial medicines under development. Clin. Pharmacol. Ther. 85:584-595.
29. Osorio L, et al. 2007. In vitro susceptibility of P. falciparum populations from Colombia and Tanzania to a new synthetic peroxide (OZ277). Am. J. Trop. Med. Hyg. 76:1024-1026. (Pubitemid 351837860)
30. Poespoprodjo JR, et al. 2008. Adverse pregnancy outcomes in an area where multidrug-resistant Plasmodium vivax and Plasmodium falciparum infections are endemic. Clin. Infect. Dis. 46:1374-1381. (Pubitemid 351589936)
31. Pradines B, Bertaux L, Pomares C, Delaunay P, Marty P. 2011. Reduced in vitro susceptibility to artemisinin derivatives associated with multi-resistance in a traveller returning from South-East Asia. Malar. J. 10:268.
32. Price RN, Douglas NM, Anstey NM. 2009. New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Curr. Opin. Infect. Dis. 22:430-435.
33. Ratcliff A, et al. 2007. Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia. Trans. R. Soc. Trop. Med. Hyg. 101:351-359. (Pubitemid 46205894)
34. Russell B, et al. 2008. Determinants of in vitro drug susceptibility testing of Plasmodium vivax. Antimicrob. Agents Chemother. 52:1040-1045. (Pubitemid 351358386)
35. Reference deleted.
36. Sharrock WW, et al. 2008. Plasmodium vivax trophozoites insensitive to chloroquine. Malar. J. 7:94.
37. Sisowath C, et al. 2009. In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. J. Infect. Dis. 199:750-757.
38. Tanariya P, Tippawangkoso P, Karbwang J, Na-Bangchang K, Wernsdorfer WH. 2000. In vitro sensitivity of Plasmodium falciparum and clinical response to lumefantrine (benflumetol) and artemether. Br. J. Clin. Pharmacol. 49:437-444. (Pubitemid 30229447)
39. Thanh NV, et al. 2010. Monitoring for Plasmodium falciparum drug resistance to artemisinin and artesunate in Binh Phuoc Province, Vietnam: 1998-2009. Malar. J. 9:181.
40. Vyas N, Avery BA, Avery MA, Wyandt CM. 2002. Carrier-mediated partitioning of artemisinin into Plasmodium falciparum-infected erythrocytes. Antimicrob. Agents Chemother. 46:105-109. (Pubitemid 34031610)
41. Waknine-Grinberg JH, et al. 2010. Artemisone effective against murine cerebral malaria. Malar. J. 9:227.
42. Wernsdorfer WH, McGregor I. 1989. Malaria: principles and practice of malariology. Churchill Livingstone, Edinburgh, Scotland.
43. Witkowski B, et al. 2010. Increased tolerance to artemisinin in Plasmodium falciparum is mediated by a quiescence mechanism. Antimicrob. Agents Chemother. 54:1872-1877.
44. Wongsrichanalai C, et al. 2001. In vitro susceptibility of Plasmodium falciparum isolates from Myanmar to antimalarial drugs. Am. J. Trop. Med. Hyg. 65:450-455. (Pubitemid 33134576)
45. World Health Organization. 2010. Guidelines for the treatment of malaria, 2nd ed. World Health Organization, Geneva, Switzerland.
46. World Health Organization. 2011. World malaria report 2011. World Health Organization, Geneva, Switzerland.